DelveInsight has launched a new report on Primary Hyperoxaluria Epidemiology
DelveInsight’s ‘Primary Hyperoxaluria Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Primary Hyperoxaluria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Primary hyperoxaluria (PH) is a rare condition characterized by recurrent kidney and bladder stones. The condition often results in end stage renal disease (ESRD), which is a life-threatening condition that prevents the kidneys from filtering fluids and waste products from the body effectively. Primary hyperoxaluria results from the overproduction of a substance called oxalate. Oxalate is filtered through the kidneys and excreted as a waste product in urine, leading to abnormally high levels of this substance in urine (hyperoxaluria). There are three types of primary hyperoxaluria that differ in their severity and genetic cause. In primary hyperoxaluria type 1, kidney stones typically begin to appear anytime from childhood to early adulthood, and ESRD can develop at any age. Primary hyperoxaluria type 2 is similar to type 1, but ESRD develops later in life. In primary hyperoxaluria type 3, affected individuals often develop kidney stones in early childhood, but few cases of this type have been described so additional signs and symptoms of this type are unclear.
Request for free sample page:- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-epidemiology-forecast
Primary hyperoxaluria Epidemiology
At present, there are no approved therapies for the treatment of Primary Hyperoxaluria and the current therapeutic market for Primary Hyperoxaluria is based on the therapies such as Enzyme reactivation therapy, Gene therapies and Substrate reduction therapy through RNA-interference. Other treatment options include Chemical chaperones, supplements intake, Hepatocyte transplantation, Dialysis whereas the general therapies for nephrolithiasis benefit all individuals with PH. Drugs such as thiazides and potassium citrate or neutral orthophosphates can decrease urinary calcium excretion and inhibit stone formation, respectively. An outline of the therapeutic strategies is currently under investigation. Treatment options for primary hyperoxaluria include alkaline citrate, orthophosphate, or magnesium. In addition, pyridoxine treatment can be used to normalize or reduce oxalate excretion in about 30% of patients with Primary Hyperoxaluria type I. Time on dialysis should be short to avoid overt systemic oxalosis.
Primary hyperoxaluria Key Facts
Primary hyperoxaluria Report Scope
Download free sample page: – https://www.delveinsight.com/sample-request/primary-hyperoxaluria-epidemiology-forecast
Table of content
1. Key Insights
2. Executive Summary of Primary Hyperoxaluria
3. Primary Hyperoxaluria: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Why should you buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/